Clinical Genetics of Familial Keloids

Marneros, Alexander G.; Norris, James E; Olsen, Bjørn R.; Reichenberger, Ernst

doi:10.1001/archderm.137.11.1429

Cited by 217 publications

(169 citation statements)

References 21 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…Keloid formation typically affects dark-skinned individuals (Fitzpatrick IV-VI skin type) to a greater extent than those with lighter skin (Fitzpatrick I-III skin type), with the majority of keloids manifesting in persons 10 to 30 years of age. 2,6,7 Younger children are still susceptible, however, as bilateral earlobe keloids have been documented in a 9-month-old African American girl 6 months after piercing. 8 In addition to differences in clinical appearance, keloids often differ histopathologically from hypertrophic scars in a variety of ways, with the most distinguishing feature being the presence of thickened hyalinized collagen (keloidal collagen).…”

Section: Scar Morphologymentioning

confidence: 99%

Scar Management in the Pediatric and Adolescent Populations

Krakowski

Totri

Donelan³

et al. 2016

Pediatrics

View full text Add to dashboard Cite

For most children and adolescents who have developed symptomatic scars, cosmetic concerns are only a portion of the motivation that drives them and their caregivers to obtain treatment. In addition to the potential for cosmetic disfigurement, scars may be associated with a number of physical comorbidities including hypertrichosis, dyshidrosis, tenderness/pain, pruritus, dysesthesias, and functional impairments such as contractures, all of which may be compounded by psychosocial factors. Although a plethora of options for treating scars exists, specific management guidelines for the pediatric and adolescent populations do not, and evidence must be extrapolated from adult studies. New modalities such as the scar team approach, autologous fat transfer, and ablative fractional laser resurfacing suggest a promising future for children who suffer symptomatically from their scars. In this state-of-the-art review, we summarize cutting-edge scar treatment strategies as they relate to the pediatric and adolescent populations.

show abstract

Section: Scar Morphologymentioning

confidence: 99%

Scar Management in the Pediatric and Adolescent Populations

Krakowski

Totri

Donelan³

et al. 2016

Pediatrics

View full text Add to dashboard Cite

show abstract

“…Several genes are considered responsible for keloid disease, but no single gene mutation has thus far been found to be responsible [32]. Genome wide association studies in Japanese population have shown that four SNP (single nucleotide polymorphism) loci in three chromosomal regions (1q41, 3q22.3-23 and 15q21.3) exhibit significant associations with keloids [33]. Marneros and colleagues studied two families with an autosomal dominant inheritance pattern of keloids (Japanese family and African American one).…”

Section: Genetic Predispositionmentioning

confidence: 99%

Comprehensive Review of Keloid Formation

Shaheen¹

2017

CRDOA

View full text Add to dashboard Cite

“…Marneros observed this phenomenon on three different generations and described an anomaly in the chromosomal loci 2q23 and 7p11 [8,9].…”

Section: Predisposing Factors For Hypertrophic and Keloid Scarsmentioning

confidence: 99%

Verapamil as Alternative Treatment in Hypertrophic and Keloid Scars

Ramos-Gallardo¹,

Delgado-Hernández²,

Cervantes-López³

et al. 2017

J Pigment Disord

View full text Add to dashboard Cite

Hypertrophic and keloid scars represent one of the main aesthetic and functional defects in patients after trauma, surgery, or burn. There are different therapeutic approaches used for these conditions, each showing varied results. Verapamil is a selective L-type calcium channel antagonist, which is currently considered as an alternative treatment in hypertrophic and keloid scars. Verapamil reduces the production of extracellular matrix, enhances collagenase secretion, and inhibits Interleukin 6 (IL-6), vascular endothelial growth factor (VEGF) and fibroblast cell proliferation. It also reduces the expression of transforming growth factor beta 1 (TGF-β1), subsequently inducing apoptosis. Verapamil is hereby proposed as an alternative and effective therapy for hypertrophic and keloid scars.

show abstract

Clinical Genetics of Familial Keloids

Cited by 217 publications

References 21 publications

Scar Management in the Pediatric and Adolescent Populations

Scar Management in the Pediatric and Adolescent Populations

Comprehensive Review of Keloid Formation

Verapamil as Alternative Treatment in Hypertrophic and Keloid Scars

Contact Info

Product

Resources

About